ArticleJGH open : an open access journal of gastroenterology and hepatology2020

Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes.

Douglas Zabrowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.